Article info
PDFBiomarker studies
Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
- Correspondence to Dr Kerry A Casey; caseyk{at}medimmune.com
Citation
Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Publication history
- Received June 19, 2018
- Revision received September 14, 2018
- Accepted September 28, 2018
- First published November 22, 2018.
Online issue publication
May 01, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/